Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 19

1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer

Date

21 Oct 2023

Session

Poster session 19

Topics

Supportive Care and Symptom Management;  Clinical Research;  Cancer Treatment in Patients with Comorbidities;  Tumour Immunology;  Immunotherapy

Tumour Site

Gastric Cancer;  Hepatobiliary Cancers;  Pancreatic Adenocarcinoma;  Gastro-Oesophageal Junction Cancer

Presenters

Hsiu-Tzu Wang

Citation

Annals of Oncology (2023) 34 (suppl_2): S619-S650. 10.1016/S0923-7534(23)01940-3

Authors

H. Wang1, M. Lin1, W. Lo1, C. Chen1, S. Wang1, C. Chiu2, E. Bai3, L. Bai1

Author affiliations

  • 1 Hematology And Oncology, China Medical University Hospital, 404 - Taichung/TW
  • 2 Cancer Center, China Medical University Hospital, 404 - Taichung/TW
  • 3 Bachelor Of Science And Art In Nutrition, UT Health Austin - The University of Texas at Austin, 78701 - Austin/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1058P

Background

Malignant ascites occur in 10 – 15% of patients with cancers from gastrointestinal tract, and it leads to impaired quality of life and declined performance. The abundance of immune cells in the peritoneum and ascites, as well as the immune escaped circumstance created by cancer cells in the peritoneum, suggest the potential use of intraperitoneal (IP) immune checkpoint inhibitors to control malignant ascites.

Methods

Patients with cancers from gastrointestinal or pancreaticobiliary tract who had cytologically confirmed malignant ascites were enrolled. Twenty mg of nivolumab diluted in 100 ml of saline was infused into the peritoneal cavity in 10 minutes after paracentesis. IP therapy was repeated after each paracentesis until ineffectiveness of therapy judged by physician, unacceptable toxicity, or patient’s refusal. The clinical response and adverse effects were recorded. The cellular components of malignant ascites sampled prior each paracentesis were analyzed by flow cytometry.

Results

Totally, 9 patients with a median age of 55 years were treated with IP nivolumab. The cancer types were pancreatic cancer in 4, biliary tract cancer in 3, and gastric cancer in 2 patients. Systemic anticancer treatments were given for 3 lines in 2, 2 lines in 2, and 1 line in 4 patients before the administration of IP nivolumab. After a median of 3 (2 – 5) cycles of treatment, 7 (77%) patients had clinical response as evidenced by reduced ascites and less frequent paracentesis. The change of tumor cell number in serial ascites, instead of the change of lymphocyte counts and lymphocyte percentage, correlated with the clinical response. There was only grade 1 tenderness over the puncture site as the adverse effect. The reasons of stop IP were death due to disease progression in 5, patient’s wish in 2, and clinical unresponsiveness in 2 patients, respectively.

Conclusions

IP administration of nivolumab was a safe and effective method to control malignant ascites from gastrointestinal or pancreaticobiliary tract cancer. Further validation of the application in larger population and other types of cancer, as well as biomarkers study are needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The National Health Research Institutes, Taiwan (NHRI-112A1-CACO-13232302) China Medical University Hospital (DMR-112-195) Ministry of Science and Technology, Taiwan (MOST110-2314-B-039-034-MY3).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.